1. Academic Validation
  2. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer

Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer

  • Chem Biol Interact. 2023 Dec 18:388:110840. doi: 10.1016/j.cbi.2023.110840.
Rin Himura 1 Shinya Kawano 1 Yujiro Nagata 2 Mina Kawai 1 Atsumi Ota 1 Yudai Kudo 1 Yuta Yoshino 1 Naohiro Fujimoto 2 Hiroshi Miyamoto 3 Satoshi Endo 4 Akira Ikari 1
Affiliations

Affiliations

  • 1 Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.
  • 2 Department of Urology, University of Occupational and Environmental Health, Kitakyushu, 807-8555, Japan.
  • 3 Departments of Pathology & Laboratory Medicine and Urology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
  • 4 Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan; Center for One Medicine Innovative Translational Research (COMIT), Gifu Pharmaceutical University, Gifu, 501-1193, Japan. Electronic address: sendo@gifu-pu.ac.jp.
Abstract

Systemic chemotherapy with gemcitabine and cisplatin (GC) has been used for the treatment of bladder Cancer in which Androgen Receptor (AR) signaling is suggested to play a critical role. However, its efficacy is often limited, and the prognosis of patients who develop resistance is extremely poor. Aldo-keto reductase 1C3 (AKR1C3), which is responsible for the production of a potent androgen, 5α-dihydrotestosterone (DHT), by the reduction of 5α-androstane-3α,17β-dione (5α-Adione), has been attracting attention as a therapeutic target for prostate Cancer that shows androgen-dependent growth. By contrast, the role of AKR1C3 in bladder Cancer remains unclear. In this study, we examined the effect of an AKR1C3 inhibitor on androgen-dependent proliferation and GC sensitivity in bladder Cancer cells. 5α-Adione treatment induced the expression of AR and its downstream factor ETS-domain transcription factor (ELK1) in both T24 cells and newly established GC-resistant T24GC cells, while it did not alter AKR1C3 expression. AKR1C3 inhibitor 2j significantly suppressed 5α-Adione-induced AR and ELK1 upregulation, as did an AR antagonist apalutamide. Moreover, the combination of GC and 2j in T24GC significantly induced apoptotic cell death, suggesting that 2j could enhance GC sensitivity. Immunohistochemical staining in surgical specimens further revealed that strong expression of AKR1C3 was associated with significantly higher risks of tumor progression and cancer-specific mortality in patients with muscle-invasive bladder Cancer. These results suggest that AKR1C3 inhibitors as adjunctive agents enhance the efficacy of GC therapy for bladder Cancer.

Keywords

AKR1C3; Androgen signaling; Bladder cancer; Chemoresistance; Gemcitabine and cisplatin therapy.

Figures
Products